Search

Objective To analyze the differences in molecular genetic characteristics between adult thalamic gliomas and brainstem gliomas to provide a basis for accurate diagnosis and treatment of adult thalamic gliomas. Methods The tumor tissue samples of 19 adult thalamic gliomas and 9 brainstem gliomas were collected. 425 tumor-related genes were detected by next-generation sequencing (NGS) . The variation in molecular genetic characteristics between adult thalamic gliomas and brainstem gliomas, such as gene point mutation and copy number variation, were analyzed. Results There was no significant difference in the incidence of diffuse midline glioma in the thalamus and brainstem of adults (P＞0. 05), but glioblastoma was more likely to occur in the thalamus (P=0. 026) . In adult thalamic gliomas, the ratio of TP53 mutation, TERT promoter mutation, CDK4/6 amplification, PTEN mutation and EGFR amplification were higher than those in adult brainstem gliomas, while the ratio of H3K27M mutation, IDH1 mutation, MCL1 amplification, NF1 mutation, ATRX mutation and FAT1 mutation were lower than those in adult brainstem gliomas. Of note, TERT promoter mutation significantly differed between adult thalamic gliomas and adult brainstem gliomas (P=0. 026) . The proportion of activation in PI3K signal pathway in adult thalamic gliomas was significantly higher compared to adult brainstem gliomas (P=0. 016) . Univariate analysis revealed that TP53 mutation (P=0. 01), CDK4/6 amplification (P=0. 02), EGFR amplification (P=0. 04) and ARID1A (P=0. 048) mutations were significantly associated with low survival in adult thalamic gliomas. In contrast, FAT1 mutation (P=0. 024) and MCL1 amplification (P=0. 017) were significantly associated with low survival in adult brainstem gliomas. Conclusions Glioblastoma is more likely to occur in adult thalamus than in brainstem, and there are significant differences in molecular genetic characteristics between the two, suggesting that adult thalamic glioma is a tumor with a special genetic tumor spectrum different from adult brain stem glioma. [ABSTRACT FROM AUTHOR]

ObjectiveTo explore the efficacy of reirradiation (re-RT) for recurrent pediatric diffuse intrinsic pontine glioma (DIPG) in China and preliminarily explore the impact of concurrent re-RT with ribociclib on the prognosis of DIPG patients. MethodsA total of 18 children with recurrent DIPG who received re-RT with or without ribociclib were recruited from Department of Oncology, Guangdong Sanjiu Brain Hospital from May 2021 to May 2023.Common Terminology Criteria for Adverse Events (CTCAE 4.0) was utilized for evaluating the occurrences of adverse reactions.Kaplan-Meier method was employed for calculating overall survival and Log-rank for examining the survival difference between two groups. ResultsThere were 5 boys and 13 girls with a median age of 7.0 years.Seven patients received concurrent reirradiation and ribociclib.Median interval between upfront radiotherapy and re-RT was 9.0 months.Among well-documented patients, 64.3%(9/14) had relieved extremity weakness, 62.5%(5/8) had improvement in slurred speech, 50% (3/6) had better walking instability and 77.8%(14/18) had tumor regression.Median survival was 4.7 months from a start of re-RT to death and overall median survival 18.6 months from an initial diagnosis.No significant difference existed in median overall survival (17.2 months vs.18.9 months)or median survival from a start of re-RT to death (6.2 months vs.5.4 months) in patients receiving re-RT plus ribociclib as compared with those without ribociclib, with P values of 0.714 and 0.390, respectively.Among 7 children receiving concurrent re-RT and ribociclib, 3 patients (42.9%) experienced hematological adverse events of CTCAE grade 1, 2 and 3. ConclusionsRe-RT may improve clinical symptoms and prolong survival time in children with recurrent DIPG.Concurrent re-RT and ribociclib therapy not only don't improve survival but also increase toxicity in children with DIPG. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Neurosurgery / Linchuang Shenjingwaike Zazhi is the property of Editorial Board of Journal of Clinical Neurosurgery and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To evaluate the safety and efficacy of stereotatic radiosurgery（SRS） in treating residual lesions of pineal non-germinomatous germ cell tumors（NGGCTs） after conventional radiotherapy. Methods The clinical data of patients with intracranial germ cell tumors admitted to Guangdong Sanjiu Brain Hospital from January 2008 to December 2018 who diagnosed with pineal NGGCTs pathologically or clinically were analyzed retrospectively. Among those, the patients received conventional radiotherapy with SRS were included. The residual lesions after radiotherapy were defined with a maximum diameter ＞10 mm. Prognosis related parameters such as local control rate, progress-free survival, overall survival and treatment-related toxicity were determined. Results Total of 27 patients were included in this study. Both of them were males with the median age of 16 years old. The median follow-up time was 34 months（range 8-142 months）. The objective response rate and disease control rate were 71.4% and 95.2%, respectively. Three-year progression-free survival rate was 85.2% and 3-year total survival rate was 88.0%. The univariate analysis revealed that both age and concurrent chemotherapy were not correlated with the prognosis（P=0.286,0.824）. Partial tumor resection before radiotherapy and chemotherapy, AFP＞500 ng/mL, and less than 4 cycles of adjuvant chemotherapy were poor prognostic factors（P=0.037,0.010,0.006）. Moreover, no acute radiation injury was observed after SRS. Only 1 out of 27 patients（ 3. 7%） had brain neurotoxicity related to a prolonged course of radiochemotherapy.Conclusions SRS for residual lesions of NGGCTs following conventional radiotherapy appears to be well tolerant and improved local control. However, the therapeutic efficacy of conventional radiotherapy combined with SRS warrants further investigations in a large-scale randomized controlled clinical trials. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To analyze the clinical characteristics and prognostic factors of single center adult brainstem glioma (ABSG), and to explore the best treatment mode.Methods The general clinical data and prognosis related information of ABSG patients were collected. The overall survival (OS) was calculated by Kaplan Meier method, the log rank test was used for univariate analysis, and the Cox regression model was used for multivariate analysis. The difference was statistically significant (P＜0. 05).Results A total of 81 ABSG were included in the analysis. The median follow-up time was 17 (3 ～ 108) months. The median OS was 18 months, and the overall survival rates at 1, 2, 3 and 5 years were 87. 4%, 75. 8%, 61. 0% and 36. 5% respectively. Univariate analysis showed that MRI enhancement, WHO pathological gradING, H3 K27 M expression, radiotherapy and maintenance chemotherapy after radiotherapy were correlated with prognosis.Multivariate Cox regression analysis showed that age, WHO pathological gradING, radiotherapy and maintenance chemotherapy after radiotherapy were independent prognostic factors.Conclusions Radiotherapy is still the main treatment of ABSG, and patients can be benefit from subsequent maintenance chemotherapy. The age ＞40 years and WHO Ⅳ grade were two independent unfavorable prognostic factors. Research with expanded patient volume would help to further explore the influence of H3 K27 M expression on ABSG prognosis. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Neurosurgery / Linchuang Shenjingwaike Zazhi is the property of Editorial Board of Journal of Clinical Neurosurgery and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Neurosurgery / Linchuang Shenjingwaike Zazhi is the property of Editorial Board of Journal of Clinical Neurosurgery and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Neurosurgery / Linchuang Shenjingwaike Zazhi is the property of Editorial Board of Journal of Clinical Neurosurgery and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)